The 22nd JFCR-ISCC

December 13 (Wed)- 14 (Thu), 2017
Miraikan (National Museum of Emerging Science and Innovation)
2-3-6, Aomi, Koto-ku, Tokyo, Japan

The 22nd JFCR-International Symposium on Cancer Chemotherapy (JFCR-ISCC) is scheduled as indicated above.
The JFCR-ISCC aims at information exchange on the latest findings of newly developing molecularly targeted anti-cancer drugs and the related topics. Molecularly targeted drugs have been developing prominently with global standards. Meanwhile, already launched molecularly targeted drugs have often been faced with intrinsic resistance, acquired resistance, and side effects. Accessing to these information is indispensable, moreover, informal exchanges of personal, very specific, or even unsuccessful experiences, are critically valuable for effective achievements of future drug development. I, as the Chairman of the JFCR-ISCC, believe the Symposium with relatively small size will provide you an excellent opportunity for such communication through personal contacts.
The topics in the upcoming 22nd JFCR-ISCC are immuno-oncology, epigenetics, patient-derived models for drug development, and first-in-class drugs. I hope the Symposium would be an excellent occasion for you to access the domestic and international developments of novel molecularly targeted anti-cancer drugs and to meet researchers in academia, hospitals and industries. So, I sincerely welcome your participation in the Symposium.
Looking forward to seeing you in Tokyo,

Naoya Fujita (Program Committee Chairman, Cancer Chemotherapy Center, JFCR)

December 13


Poster mounting


Committee meeting

Opening Remark


Naoya Fujita (Cancer Chemotherapy Center, JFCR, Tokyo)

Opening remark

I Genetic biomarkers and rational combinations for cancer immunotherapy

Chairpersons: Bruce A. Chabner (MGH/Harvard Medical School, Boston, MA, USA)
Atsushi Ohtsu (National Cancer Center Hospital East, Chiba)


Scott K. Pruitt (Merck Research Laboratories, Rahway, NJ, USA)

The first tumor-type agnostic regulatory approval: Pembrolizumab for the treatment of advanced MSI-H/dMMR cancer


Philip J. Stephens (Foundation Medicine, Inc., Cambridge, MA, USA)

Identification of novel modulators of response to immune checkpoint blockade in lung cancer patients through the marrying of clinical and genomic data




Coffee break

II Sophisticated DNA damage inducers for cancer therapy

Chairpersons: Shunichi Takeda (Kyoto University, Kyoto)
Hiroyuki Seimiya (Cancer Chemotherapy Center, JFCR, Tokyo)


Yves G. Pommier (National Cancer Institute, NIH, Bethesda, MD, USA)

PARP trapping and replicative damages


Hiroki Nagase (Chiba Cancer Center Research Institute, Chiba)

Targeting the Achilles’ heel of cancer: Sequence specific alkylation at KRAS driver gene DNA mutations



Poster Flash Talks

Chairperson: Ryohei Katayama (Cancer Chemotherapy Center, JFCR, Tokyo)


Takahiro Komatsu (Daiichi Sankyo Co., Ltd., Tokyo)

DS-1205b, a novel selective AXL inhibitor delays the onset of resisitance to EGFR-TKIs in a human EGFR‐mutant NSCLC ﴾T790M‐negative﴿ xenograft model

Kotaro Okada (Cancer Chemotherapy Center, JFCR, Tokyo)

1st or 2nd generation ALK-TKI rescues the next-generation ALK-TKI resistance mediated by double mutations

Tohru Kotani (Ono Pharmaceutical Co., Ltd., Osaka)

ONO-AE3-208 promotes anti-tumor immune activity and survival in glioma models

Munetoshi Ando (Kyowa Hakko Kirin Co., Ltd., Shizuoka)

ADCC activity of KHK2805 with IP-10 production is one of anti-cancer mechanisms in platinum resistant ovarian cancer preclinical models

Tetsuro Yoshimaru (Tokushima University, Tokushima)

Stapled BIG3 helical peptide ERAP potentiates anti-tumor activity for endocrine-resistant breast cancer therapeutics

Daisuke Okajima (Daiichi Sankyo Co., Ltd., Tokyo)

DS-1062a, a novel TROP2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a potent anti-tumor efficacy

Takefumi Onodera (Institute of Microbial Chemistry, Shizuoka)

Auranofin exhibits preferential cytotoxicity to human pancreatic cancer cells under nutrient-deprived conditions

Kei Takahashi (The University of Tokyo, Tokyo)

Evaluation of anti-tumor drug effects with CUBIC-cancer analysis

Poster Session & Mixer



December 14

III New technologies and drugs under clinical or preclinical investigations

Chairpersons: Michael Axelson (Bristol-Myers Squibb KK, Tokyo)
Shunji Takahashi (The Cancer Institute Hospital of JFCR, Tokyo)


Pablo Umaña (Roche Glycart AG, Schlieren, Switzerland)

CEA-TCB: A novel bispecific antibody targeting solid tumors


Antoine Yver (Daiichi Sankyo, Inc., Basking Ridge, NJ, USA)

Clinical study results of DS-8201a, a novel HER2-targeting ADC with a DNA topoisomerase I inhibitor.


Lothar Finke (Incyte Biosciences Japan GK, Tokyo)

Targeting IDO1 in the TME: A novel approach to combination immunotherapy for cancer




Coffee break

Poster Discussion Session

Chairperson: Manabu Kawada (Institute of Microbial Chemistry, Tokyo)


Mentor: 1: Bruce A. Chabner   Poster #: P1-P4

Mentor: 2: Yves G. Pommier    Poster #: P5-P8

Luncheon Seminar (Supported by Charles River Laboratories Japan, Inc.)


Thomas Metz (Charles River Discovery Research Services GmbH, Freiburg, Germany)

Preclinical in vivo profiling of i/o and non i/o anti-cancer agents: Optimization of model selection


Poster removal

IV Drug discovery and preclinical evaluation using cellular and patient-derived models
(Supported by MEXT Grant-in-Aid for Scientific Research on Innovative Areas "Integrated Analysis and Regulation of Cellular Diversity (4904)")

Chairpersons: Yves G. Pommier (National Cancer Institute, NIH, Bethesda, MD, USA)
Shingo Dan (Cancer Chemotherapy Center, JFCR, Tokyo)


Andrew Schile (The Jackson Laboratory, Sacramento, CA, USA)

“Onco-Hu” mouse model for evaluating immuno-oncology therapeutics


Masahiro Inoue (Osaka International Cancer Institute, Osaka)

Drug screening by use of a panel of primary cultured cancer spheroids derived from clinical tumor samples



Special Lecture

Chairperson: Mitsuaki Yoshida (Cancer Chemotherapy Center, JFCR, Tokyo)


Bruce A. Chabner (MGH/Harvard Medical School, Boston, MA, USA)

Challenges and opportunities for targeted therapies




Coffee break

V Next generation of combination cancer immunotherapy
(Supported by Bristol-Myers Squibb)

Chairpersons: Phil Stephens (Foundation Medicine, Inc., Cambridge, MA, USA)
Ryuzo Ueda (Aichi Medical University, Aichi)


Bruce D. Car (Bristol-Myers Squibb, Lawrenceville, NJ, USA)

Overview of IO drug development


Michael Axelson (Bristol-Myers Squibb KK, Tokyo)

Overview of Immuno-Oncology clinical development for combinations of checkpoint inhibitors


Hiroyoshi Nishikawa (Research Institute, EPOC, National Cancer Center, Chiba / Nagoya University, Aichi)

Genome-immune analyses to decipher anti-tumor immune responses



Closing Remark


Bruce A. Chabner (MGH/Harvard Medical School, Boston, MA, USA)

Closing remark

Page Top